 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

ROCHESTER, N.Y., Sept. 28, 2023 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX) ( Vaccinex or the Company ), a clinical-stage biotechnology company pioneering a differentiated approach to...

Vaccinex Announces Pricing of $9.6 Million Public Offering

See the rest of the story here.

thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...

Vaccinex to present update on PDAC/Pepinemab study, new ActivMAb application

Phase 1b/2 pepinemab/PDAC study update to be presented on September 29 at special AACR meeting New ActivMAb application to be reviewed on September 28 at CHI's 20th Annual Discovery on...

Vaccinex to Present Update on PDAC/Pepinemab Study; New ActivMAb  Application

Vaccinex reports findings at medical conferences on Pepinemab

Figure 1. Treatment with pepinemab in combination with KEYTRUDA appears to induce formation of highly organized lymphoid structures in tumors that correlate with disease control...

Vaccinex Reports Groundbreaking Findings at Medical Conferences Supporting Development of Pepinemab for the Treatment of Neurodegenerative Diseases and Cancer

ROCHESTER, N.Y., Sept. 22, 2023 (GLOBE NEWSWIRE) -- Vaccinex, Inc., (NASDAQ: VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating neurodegenerative disease...

Vaccinex, Inc. Announces Reverse Stock Split

Vaccinex reports Q2 EPS (12c) vs (13c) last year

Phase 1/2a SIGNAL-AD Study of Pepinemab in Alzheimers Disease Achieves Full Accrual Expect to Complete 12-months treatment in June, 2024 Promising Interim Results for KEYNOTE-B84 Phase 2 Trial in Head and Neck Cancer ROCHESTER, N.Y., Aug. 14, 2023 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a...

Vaccinex Reports Second Quarter 2023 Financial Results and Provides Corporate Update

Vaccinex, Inc. (NASDAQ:VCNX Get Rating) was the recipient of a large decrease in short interest during the month of May. As of May 31st, there was short interest totalling 99,500 shares, a decrease of 30.5% from the May 15th total of 143,100 shares. Currently, 0.5% of the shares of the stock are ...

Vaccinex, Inc. (NASDAQ:VCNX) Short Interest Down 30.5% in May

Vaccinex, Inc. (NASDAQ:VCNX  Get Rating) saw a significant drop in short interest in the month of May. As of May 31st, there was short interest totalling 99,500 shares, a drop of 30.5% from the May 15th total of 143,100 shares. Currently, 0.5% of the companys stock are short sold. ...

Vaccinex, Inc. (NASDAQ:VCNX) Short Interest Update

Vaccinex, Inc. operates as a clinical-stage biotechnology company. It engages in the development of targeted bio therapeutics to treat serious diseases and conditions with unmet medical needs, including cancer, neurodegenerative diseases, and autoimmune disorders. The firm focuses on the development of Pepinemab for the treatment of non-small cell lung cancer, or NSCLC, osteosarcoma, melanoma, and Huntington’s disease. Its product pipeline includes the SEMA4D antibody platform and ActivMAb antibody discovery platform. The company was founded by Maurice Zauderer in April 2001 and is headquartered in Rochester, NY.

Watchers	5,200
52-Wk Low	$1.00
52-Wk High	$12.36

Market Cap	$4.7M
Volume (M)	204,014.00
52-Wk High	$12.36
52-Wk Low	$1.00

VCNX Vaccinex Inc

About

Feed

News

Sentiment

Fundamentals